Trials / Unknown
UnknownNCT03981536
A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- AL-S Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Single ascending doses of AP-101 will be administered by intravenous (IV) infusion
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AP-101 | Administered by intravenous infusion (IV) |
Timeline
- Start date
- 2019-10-10
- Primary completion
- 2020-11-02
- Completion
- 2020-11-02
- First posted
- 2019-06-11
- Last updated
- 2020-10-27
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03981536. Inclusion in this directory is not an endorsement.